GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getein Biotech Inc (SHSE:603387) » Definitions » EV-to-EBITDA

Getein Biotech (SHSE:603387) EV-to-EBITDA : 15.25 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Getein Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Getein Biotech's enterprise value is ¥4,287 Mil. Getein Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥281 Mil. Therefore, Getein Biotech's EV-to-EBITDA for today is 15.25.

The historical rank and industry rank for Getein Biotech's EV-to-EBITDA or its related term are showing as below:

SHSE:603387' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.16   Med: 17.55   Max: 47.5
Current: 15.25

During the past 12 years, the highest EV-to-EBITDA of Getein Biotech was 47.50. The lowest was 7.16. And the median was 17.55.

SHSE:603387's EV-to-EBITDA is ranked better than
53.2% of 485 companies
in the Medical Devices & Instruments industry
Industry Median: 16.32 vs SHSE:603387: 15.25

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Getein Biotech's stock price is ¥8.96. Getein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.480. Therefore, Getein Biotech's PE Ratio for today is 18.67.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Getein Biotech EV-to-EBITDA Historical Data

The historical data trend for Getein Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getein Biotech EV-to-EBITDA Chart

Getein Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.82 19.39 12.38 9.21 13.23

Getein Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.64 16.71 19.78 13.23 16.19

Competitive Comparison of Getein Biotech's EV-to-EBITDA

For the Medical Devices subindustry, Getein Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Getein Biotech's EV-to-EBITDA falls into.



Getein Biotech EV-to-EBITDA Calculation

Getein Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4286.960/281.156
=15.25

Getein Biotech's current Enterprise Value is ¥4,287 Mil.
Getein Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥281 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getein Biotech  (SHSE:603387) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Getein Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.96/0.480
=18.67

Getein Biotech's share price for today is ¥8.96.
Getein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.480.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Getein Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Getein Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Getein Biotech (SHSE:603387) Business Description

Traded in Other Exchanges
N/A
Address
No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
Executives
Su En Kui Director
Yan Bin Director
Kong Ting Ting Director
Xu Xing De Director
Su En Ben Director

Getein Biotech (SHSE:603387) Headlines

No Headlines